Vitamin D and its metabolites are best known for their actions in calcium and bone metabolism. However, epidemiological studies have suggested that an increased prostate cancer risk is associated with decreased production of vitamin D. in vitro and in vivo studies have shown that the biologically active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25D), inhibits proliferation of cancer cells derived from multiple tissues, including the prostate. Although the mechanisms underlying the growth inhibitory effects of 1,25D have not been fully elucidated, in prostate cancer cells 1,25D reduces cell growth via a number of cellular pathways, including cell cycle arrest, induction of apoptosis, and altered activation of growth factor signaling. The hypercalcemia induced by 1,2SD in vivo limits its use clinically as a therapeutic agent. However, several 1,25D analogs have been developed that reduce prostate tumor growth in rodent xenograft models without causing hypercalcemia. Additional studies are required in order to determine whether these 1,25D analogs will be useful therapeutic agents for the treatment of prostate cancer.
JonesG, StrugnellSA, DeLucaHF. Current understanding of the molecular actions of vitamin D. Physiol Rev78:1193–1231, 1998.
4.
SchwartzGG, WhitlatchLW, ChenTC, LokeshwarBL, HolickMF. Human prostate cells synthesize 1, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev7:391–395, 1998.
5.
HausslerM, MangelsdorfDJ, KommBS, TerpeningCM, YamazakiK, AllegrettoEA, BakerAR, ShineJ, McDonnellTJ, HughesM, WeigelNL, O'malleyBW, PikeJW. Molecular biology of the vitamin D hormone. Recent Prog Horm Research44:263–305, 1988.
6.
PeehlDM, SkowronskiRJ, LeungGK, WongST, StameyTA, FeldmanD.Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res54:805–810, 1994.
7.
SprengerCC, PetersonA, LanceR, WareJL, DrivdahlRH, PlymateSR. Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol170:609–618, 2001.
8.
KrillD, StonerJ, KonetyBR, BecichMJ, GetzenbergRH. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology54:171–177, 1999.
9.
BarretoAM, SchwartzGG, WoodruffR, CramerSD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev9:265–270, 2000.
10.
ChenTC, SchwartzGG, BurnsteinKL, LokeshwarBL, HolickMF. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1535370204229004011alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res6:901–908, 2000.
11.
KonetyBR, LemanE, VietmeierB, ArlottiJ, DhirR, GetzenbergRH. in Vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate. J Urol164:1812–1818, 2000.
12.
HsuJY, FeldmanD, McNealJE, PeehlDM. Reduced 1alphahydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res61:2852–2856, 2001.
13.
SchwartzGG, HulkaBS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res10:1307–1311, 1990.
14.
HanchetteCL, SchwartzGG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer70:2861–2869, 1992.
15.
MacLaughlinJ, HolickM.Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest76:1536–1538, 1985.
16.
MatsuokaL, WortsmanJ, HaddadJ, KolmP, HollisB.Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol127:536–538, 1991.
17.
CorderEH, GuessHA, HulkaBS, FriedmanGD, SadlerM, VollmerRT, LobaughB, DreznerMK, VogelmanJH, OrentreichN.Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev2:467–472, 1993.
18.
BraunMM, HelzlsouerKJ, HollisBW, ComstockGW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control6:235–239, 1995.
19.
GannPH, MaJ, HennekensCH, HollisBW, HaddadJG, StampferMJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev5:121–126, 1996.
20.
NomuraAM, StemmermannGN, LeeJ, KolonelLN, ChenTC, TurnerA, HolickMF. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control9:425–432, 1998.
21.
AhonenMH, TenkanenL, TeppoL, HakamaM, TuohimaaP.Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control11:847–852, 2000.
22.
WhitlatchL, YoungM, SchwartzG, FlanaganJ, BurnsteinK, LokeshwarB, RichE, HolickM, ChenT.25-Hydroxyvitamin D-1535370204229004011alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol81:135–140, 2002.
23.
MillerGJ, StapletonGE, FerraraJA, LuciaMS, PfisterS, HedlundTE, UpadhyaP.The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for I alpha,25-dihydroxyvitamin D3. Cancer Res52:515–520, 1992.
24.
BluttSE, AllegrettoEA, PikeJW, WeigelNL. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology138:1491–1497, 1997.
25.
SkowronskiRJ, PeehlDM, FeldmanD.Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology132:1952–1960, 1993.
26.
PolekTC, StewartLV, RyuEJ, CohenMB, AllegrettoEA, WeigelNL. p53 is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology144:50–60, 2003.
27.
ZhaoXY, PeehlDM, NavoneNM, FeldmanD.1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgendependent and androgen-independent mechanisms. Endocrinology141:2548–2556, 2000.
28.
NemereI, DormanenMC, HammondMW, OkamuraWH, NormanAW. Identification of a specific binding protein for 1 alpha,25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem269:23750–23756, 1994.
HedlundTE, MoffattKA, MillerGJ. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol58:277–288, 1996.
31.
HedlundTE, MoffattKA, MillerGJ. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology137:1554–1561, 1996.
32.
ZhuangSH, SchwartzGG, CameronD, BurnsteinKL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol126:83–90, 1997.
33.
ZhaoXY, LyLH, PeehlDM, FeldmanD.1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgendependent. Endocrinology138:3290–3298, 1997.
34.
YangES, MaiorinoCA, RoosBA, KnightSR, BurnsteinKL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol186:69–79, 2002.
35.
RaoA, WoodruffR, WadeW, KuteT, CramerS.Genistein and vitamin D synergistically inhibit prostatic epithelial cell growth. J Nutr132:3191–3194, 2002.
36.
ZhuangSH, BurnsteinKL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology139:1197–1207, 1998.
37.
BluttSE, McDonnellTJ, PolekTC, WeigelNL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology141:10–17, 2000.
38.
ZetterbergA, LarssonO, WimanKG. What is the restriction point? Curr Opin Cell Biol7:835–842, 1995.
39.
GrossC, SkowronskiR, PlymateS, RhimJ, PeehlD, FeldmanD.Simian virus 40-, but not human papillomavirus, transformation of prostatic epithelial cells results in loss of growth inhibition by 1,25 dihydroxyvitamin D3. Int J Oncol8:41–47, 1996.
40.
YangE, BurnsteinK.Vitamin D inhibits GI to S progression in LNCaP prostate cancer cells through p27kipl stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem287:46862–46868, 2003.
41.
MoffattKA, JohannesWU, HedlundTE, MillerGJ. Growth inhibitory effects of 1 alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res61:7122–7129, 2001.
42.
BartekJ, LucasJ.Pathways governing G1/S transition and their response to DNA damage. FEBS Lett490:117–122, 2001.
43.
JensenS, MadsenM, LukasJ, BinderupL, BartekJ.Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol15:1370–1380, 2001.
44.
MathiasenIS, LademannU, JaattelaM.Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res59:4848–4856, 1999.
45.
NarvaezCJ, WelshJ.Role of mitochondria and caspases in vitamin D mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem276:9101–9107, 2000.
46.
HsiehT, WuJM. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun235:539–544, 1997.
47.
FifeRS, SledgeGWJr, ProctorC.Effects of vitamin D3 on proliferation of cancer cells in vitro.Cancer Lett120:65–69, 1997.
48.
GuzeyM, KitadaS, ReedJ.Apoptosis induction by 1a,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther1:667–677, 2002.
49.
ChanJM, StampferMJ, GiovannucciE, GannPH, MaJ, WilkinsonP, HennekensCH, PollakM.Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science279:563–566, 1998.
50.
PlatzE, PollakM, RimmE, MajeedN, TaoY, WillettW, GiovannucciE.Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev8:1107–1110, 1999.
51.
ChokkalingamA, PollakM, FillmoreC, GaoY, StanczykF, DengJ, SesterhennI, MostofiF, FearsT, MadiganM, ZieglerR, FraumeniJJ, HsingA.Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev10:421–427, 2001.
52.
ChanJ, StampferM, MaJ, GannP, GazianoJ, PollakM, GiovannucciE.Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst94:1099–1106, 2002.
53.
GrimbergA, CohenP.Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol183:1–9, 2000.
54.
HuynhH, PollakM, ZhangJC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol13:137–143, 1998.
55.
DrivdahlRH, LoopSM, AndressDL, OstensonRC. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate26:72–79, 1995.
56.
MartinJL, PattisonSL. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology141:2401–2409, 2000.
57.
BoyleBJ, ZhaoXY, CohenP, FeldmanD.Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAFl. J Urol165:1319–1324, 2001.
58.
PiekE, RobertsAB. Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res83:1–54, 2001.
MurthyS, WeigelN.1a,25-Dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate (in press)
61.
Tovar SepulvedaVA, FalzonM.Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept105:109–120, 2002.
62.
Tovar SepulvedaVA, FalzonM.Regulation of PTH-related protein gene expression by vitamin D in PC-3 prostate cancer cells. Mol Cell Endocrinol190:115–124, 2002.
63.
Tovar SepulvedaVA, FalzonM.Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE. Mol Cell Endocrinol204:51–64, 2003.
64.
CampbellMJ, GombartAF, KwokSH, ParkS, KoefflerHP. The antiproliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene19:5091–5097, 2000.
65.
QiaoS, PennanenP, NazarovaN, LouY, TuohimaaP.Inhibition of fatty acid synthase expression by 1a,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol85:1–8, 2003.
66.
DeSchrijverE, BrusselmansK, HeynsW, VerhoevenG, SwinnenJ.RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res63:3799–3804, 2003.
67.
ZhaoXY, LyLH, PeehlDM, FeldmanD.Induction of androgen receptor by 1 alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology140:1205–1212, 1999.
68.
LyLH, ZhaoXY, HollowayL, FeldmanD.Liarozole acts synergistically with 1 alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology140:2071–2076, 1999.
69.
MoffattKA, JohannesWU, MillerGJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res5:695–703, 1999.
70.
DunlapN, SchwartzGG, EadsD, CramerSD, SherkAB, JohnV, KoumenisC.1Alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1535370204229004011alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer89:746–753, 2003.
71.
AhmedS, JohnsonCS, RuegerRM, TrumpDL. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol168:756–761, 2002.
72.
SkowronskiRJ, PeehlDM, FeldmanD.Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology136:20–26, 1995.
73.
BauerJA, ThompsonTA, ChurchDR, AriaziEA, WildingG.Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. Prostate55:159–167, 2003.
74.
de VosS, HoldenS, HeberD, ElstnerE, BinderupL, UskokovicM, RudeB, ChenDL, LeJ, ChoSK, KoefflerHP. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate31:77–83, 1997.
75.
HisatakeJ, KubotaT, HisatakeY, UskokovicM, TomoyasuS, KoefflerHP. 5,6-Trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res59:4023–4029, 1999.
76.
HisatakeJ, O'kellyJ, UskokovicMR, TomoyasuS, KoefflerHP. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood97:2427–2433, 2001.
77.
HedlundTE, MoffattKA, UskokovicMR, MillerGJ. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res3:1331–1338, 1997.
78.
KoikeM, KoshizukaK, KawabataH, YangR, TaubHE, SaidJ, UskokovicM, TsuruokaN, KoefflerHP. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Anticancer Res19:1689–1697, 1999.
79.
ElstnerE, CampbellMJ, MunkerR, ShintakuP, BinderupL, HeberD, SaidJ, KoefflerHP. Novel 20-epi-vitamin D3 analog combined with 9-cis retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate40:141–149, 1999.
80.
RoyS, MartelJ, TenenhouseH.Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase. J Bone Miner Res10:1951–1959, 1995.
81.
PelegS, IsmailA, UskokovicM, AvnurZ.Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem88:267–273, 2003.
82.
CrescioliC, MaggiM, LuconiM, VannelliGB, SalernoR, SinisiAA, BonaccorsiL, FerruzziP, BarniT, FortiG, SerioM.Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate50:15–26, 2002.
83.
OadesG, DredgeK, KirbyR, ColstonK.Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int90:607–616, 2002.
84.
SchwartzGG, HillCC, OelerTA, BecichMJ, BahnsonRR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.Urology46:365–369, 1995.
85.
BluttSE, PolekTC, StewartLV, KattanMW, WeigelNL. A calcitriol analogue, EB 1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res60:779–782, 2000.
86.
LokeshwarBL, SchwartzGG, SelzerMG, BumsteinKL, ZhuangSH, BlockNL, BinderupL.Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev8:241–248, 1999.
87.
GetzenbergRH, LightBW, LapcoPE, KonetyBR, NangiaAK, AciernoJS, DhirR, ShurinZ, DayRS, TrumpDL, JohnsonCS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology50:999–1006, 1997.
88.
VegesnaV, O'kellyJ, SaidJ, UskokovicM, BinderupL, KoefflerH.Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res23:283–290, 2003.
89.
BoehmMF, FitzgeraldP, ZouA, ElgortMG, BischoffED, MereL, MaisDE, BissonnetteRP, HeymanRA, NadzanAM, ReichmanM, AllegrettoEA. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem Biol6:265–275, 1999.
90.
PolekTC, MurthyS, BluttSE, BoehmMF, ZouA, WeigelNL, AllegrettoEA. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate49:224–233, 2001.
91.
MantellDJ, OwensPE, BundredNJ, MawerEB, CanfieldAE. 1alpha,25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo.Circ Res87:214–220, 2000.
92.
IsekiK, TatsutaM, UeharaH, IishiH, YanoH, SakaiN, IshiguroS.Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer81:730–733, 1999.
93.
BernardiR, JohnsonC, ModzelewskiR, TrumpD.Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology143:2508–2514, 2002.
94.
SungV, FeldmanD.1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol164:133–143, 2000.
95.
GrossC, StameyT, HancockS, FeldmanD.Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol159:2035–2039, 1998.
96.
BeerT, LemmonD, LoweB, HennerW.High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer97:1217–1224, 2003.
97.
LiuG, OettelK, RippleG, StaabMJ, HorvathD, AlbertiD, ArzoomanianR, MarnochaR, BruskewitzR, MazessR, BishopC, BhattacharyaA, BaileyH, WildingG.Phase I trial of 1alphahydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res8:2820–2827, 2002.
98.
BeerT, EilersK, GarzottoM, EgorinM, LoweB, HennerW.Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol21:123–128, 2003.
